Why the study?
Do phosphodiesterase III inhibitors reduce total mortality in symptomatic patients with chronic heart failure?
Do phosphodiesterase III inhibitors reduce total mortality in symptomatic patients with chronic heart failure?
Chronic use of phosphodiesterase III inhibitors in patients with chronic heart failure increases mortality and should be avoided.
No takes yet. Share an insight, caveat, or question.
PDIs increase mortality in chronic HF and should be avoided; confirms and strengthens prior RCT evidence of harm.
Amsallem et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: